<SEC-DOCUMENT>0001193125-24-001013.txt : 20240103
<SEC-HEADER>0001193125-24-001013.hdr.sgml : 20240103
<ACCEPTANCE-DATETIME>20240103070658
ACCESSION NUMBER:		0001193125-24-001013
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20240103
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240103
DATE AS OF CHANGE:		20240103

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Invivyd, Inc.
		CENTRAL INDEX KEY:			0001832038
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				851403134
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40703
		FILM NUMBER:		24504335

	BUSINESS ADDRESS:	
		STREET 1:		1601 TRAPELO ROAD
		STREET 2:		SUITE 178
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
		BUSINESS PHONE:		(781) 819-0080

	MAIL ADDRESS:	
		STREET 1:		1601 TRAPELO ROAD
		STREET 2:		SUITE 178
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Adagio Therapeutics, Inc.
		DATE OF NAME CHANGE:	20201112
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d277393d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ivvd="http://invivyd.com/20240103" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2024-01-03_to_2024-01-03">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2024-01-03_to_2024-01-03">0001832038</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="ivvd-20240103.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2024-01-03_to_2024-01-03"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001832038</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-03</xbrli:startDate> <xbrli:endDate>2024-01-03</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2024-01-03_to_2024-01-03">8-K</ix:nonNumeric></span></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2024-01-03_to_2024-01-03" format="ixt:datemonthdayyearen">January&#160;3, 2024</ix:nonNumeric></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2024-01-03_to_2024-01-03">Invivyd, Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact Name of Registrant as Specified in its Charter)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2024-01-03_to_2024-01-03" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2024-01-03_to_2024-01-03">001-40703</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2024-01-03_to_2024-01-03">85-1403134</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or Other Jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of Incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2024-01-03_to_2024-01-03">1601 Trapelo Road</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2024-01-03_to_2024-01-03">Suite 178</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2024-01-03_to_2024-01-03">Waltham</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2024-01-03_to_2024-01-03">MA</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2024-01-03_to_2024-01-03">02451</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2024-01-03_to_2024-01-03">(781)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2024-01-03_to_2024-01-03">819-0080</ix:nonNumeric></span></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2024-01-03_to_2024-01-03" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2024-01-03_to_2024-01-03" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2024-01-03_to_2024-01-03" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2024-01-03_to_2024-01-03" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2024-01-03_to_2024-01-03">Common stock, par value $0.0001 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2024-01-03_to_2024-01-03">IVVD</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2024-01-03_to_2024-01-03" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">Emerging growth company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2024-01-03_to_2024-01-03" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;<ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2024-01-03_to_2024-01-03" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;8.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&#160;3, 2024, Invivyd, Inc. issued a press release entitled &#8220;Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the Pre-exposure Prevention of <span style="white-space:nowrap">COVID-19</span> in Immunocompromised Adults and Adolescents.&#8221; A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference in this Item 8.01. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:93%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Exhibit</span><br /><span style="font-weight:bold">No.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d277393dex991.htm">Press Release, dated January&#160;3, 2024 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">INVIVYD, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: January&#160;3, 2024</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jill Andersen</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Jill Andersen</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Chief Legal Officer and Corporate Secretary</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d277393dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g277393g0103035319803.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>VYD222 for the Pre-exposure Prevention of <FONT STYLE="white-space:nowrap">COVID-19</FONT> in Immunocompromised </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Adults and Adolescents </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>EUA submission is based on positive initial results from the ongoing CANOPY Phase 3 pivotal clinical trial and
ongoing in vitro neutralization activity against relevant <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> variants</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>VYD222 demonstrates continued in vitro neutralization activity against major <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> variants, including JN.1, currently the fastest growing variant in the U.S. </I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Company continues preparations for potential commercial launch if EUA is granted</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WALTHAM, Mass., January&nbsp;3, 2024 (GLOBE NEWSWIRE) &#150; Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable
from serious viral infectious diseases, today announced that it has requested Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for VYD222, a broadly neutralizing, half-life extended monoclonal antibody candidate,
for the <FONT STYLE="white-space:nowrap">pre-exposure</FONT> prevention of <FONT STYLE="white-space:nowrap">COVID-19</FONT> in immunocompromised adults and adolescents. The EUA submission was based on positive initial results from the CANOPY Phase 3
pivotal clinical trial of VYD222, as well as ongoing <I>in vitro</I> neutralization activity against relevant variants such as JN.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are
tremendously pleased by the fact that VYD222 continues to demonstrate <I>in vitro</I> neutralization activity against the latest dominant variant, JN.1, as well as other prevalent
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> strains,&#148; said Dave Hering, Chief Executive Officer of Invivyd. &#147;We believe that the demonstrated durability of VYD222 is reflective of our strategy
to select antibody candidates that target conserved epitopes to achieve our stated goal of keeping pace with viral evolution.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Hering
added, &#147;The submission of the EUA request for<B></B>&nbsp;VYD222&nbsp;represents an exciting milestone for&nbsp;Invivyd<B> </B>that was only made possible thanks to the unwavering dedication of our employees, the support of our investigators,
and the invaluable contributions of all those who participated in the CANOPY&nbsp;trial. Many immunocompromised people do not achieve full benefit from <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccines as their immune systems are unable to
provide sufficient defense against <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2.</FONT></FONT><I> </I>If authorized, we believe VYD222 could provide these vulnerable individuals with an important new preventive
option.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Seth Ginsberg, President and <FONT STYLE="white-space:nowrap">Co-Founder,</FONT> Global Healthy Living Foundation, commented, &#147;We are
eagerly tracking the progress of new monoclonal antibodies because there are still countless immunocompromised people who remain vulnerable to the ravages of <FONT STYLE="white-space:nowrap">COVID-19.</FONT> Sustained innovation is what is needed to
keep pace with this virus, and we commend Invivyd and others working in this space for their commitment and dedication to serving those who are in urgent need of protection.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;18, 2023, Invivyd announced positive initial results from the ongoing CANOPY pivotal clinical trial. VYD222 produced high serum virus
neutralizing antibody (sVNA) titer levels against XBB.1.5 in the immunocompromised cohort. The company observed an encouraging, potential early signal of strong clinical protection from symptomatic <FONT STYLE="white-space:nowrap">COVID-19</FONT> in
CANOPY, which would be expected based on the high sVNA titer levels and dose selected. In addition, the company believes that the initial results from CANOPY support an immunobridging approach which utilizes <I>in vitro</I> VYD222 potency data to
calculate and efficiently determine the sVNA titer levels against new <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> variants as they emerge. Initial results showed that the safety and tolerability profile
of VYD222 remained favorable with no study drug related serious adverse events reported; adverse events attributed to VYD222 were Grade 1 or 2 (mild or moderate) in severity.<I> </I> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>In vitro</I> pseudovirus testing shows that VYD222 has potency against various <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> variants currently circulating, including JN.1, which is currently the fastest growing variant in the U.S., as well as HV.1, BA.2.86, XBB.1.5.10/EG.5, and HK.3.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If authorized, Invivyd aims to have VYD222 commercially available rapidly thereafter. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About CANOPY </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The CANOPY pivotal clinical trial is an
ongoing Phase 3 clinical trial designed to evaluate protection against symptomatic <FONT STYLE="white-space:nowrap">COVID-19</FONT> after receiving VYD222. The safety, tolerability, pharmacokinetic profile, and immunogenicity of VYD222 will also be
evaluated. In November 2023, Invivyd announced the completion of enrollment in the CANOPY clinical trial, with approximately 750 participants enrolled in two cohorts (A and B) across multiple trial sites in the U.S.&nbsp;Cohort A enrolled
approximately 300 participants who are significantly immunocompromised. For this cohort, the primary endpoints include safety and tolerability and serum neutralizing titers against relevant <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> variants at Day 28, which will be calculated based on the pharmacokinetic concentration of VYD222 from the immunocompromised participants and the IC50&nbsp;value for VYD222 against relevant <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> variants. The primary efficacy analysis uses an immunobridging approach comparing data obtained in the CANOPY clinical trial to certain historical data from the
company&#146;s previous Phase 2/3 clinical trial of adintrevimab (ADG20) for the prevention of symptomatic <FONT STYLE="white-space:nowrap">COVID-19</FONT> (EVADE), in which serum neutralizing titers correlated with observed clinical efficacy. All
Cohort A participants received VYD222 administered via intravenous (IV)&nbsp;infusion.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cohort B enrolled approximately 450 participants at risk of
exposure to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2.</FONT></FONT> Participants were randomized 2:1 to receive VYD222 or placebo administered via IV infusion.&nbsp;The primary endpoints include safety and
tolerability and the proportion of participants with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">RT-PCR-confirmed</FONT></FONT> symptomatic <FONT STYLE="white-space:nowrap">COVID-19</FONT> through 6 months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Invivyd is evaluating the 4500 mg dose of VYD222 in the CANOPY clinical trial. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About VYD222 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VYD222 is a broadly neutralizing, half-life
extended monoclonal antibody (mAb) candidate in development for the prevention of symptomatic <FONT STYLE="white-space:nowrap">COVID-19</FONT> in vulnerable populations, such as immunocompromised people. Globally, there are millions of
immunocompromised people, with more than 9&nbsp;million in the U.S. alone who may not adequately respond to <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccination, increasing their risk for severe outcomes from
<FONT STYLE="white-space:nowrap">COVID-19.</FONT> Currently, there are no monoclonal antibodies authorized or approved in the U.S. for the prevention of symptomatic <FONT STYLE="white-space:nowrap">COVID-19.&nbsp;VYD222</FONT> was designed for broad
activity and has demonstrated<I>&nbsp;in vitro</I>&nbsp;neutralizing activity in pseudovirus assays against various <FONT STYLE="white-space:nowrap">pre-Omicron</FONT> and Omicron variants, such as JN.1, HV.1, BA.2.86, XBB.1.5.10/EG.5, and HK.3.
VYD222 was engineered from adintrevimab, Invivyd&#146;s investigational mAb that has a robust safety data package and demonstrated clinically meaningful results in global Phase 2/3 clinical trials for both the prevention and treatment of <FONT
STYLE="white-space:nowrap">COVID-19.</FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Invivyd </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company on a mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable
people from the devastating consequences of circulating viral threats, beginning with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2.</FONT></FONT> The company&#146;s proprietary INVYMAB<SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP> platform approach combines <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art</FONT></FONT></FONT> viral surveillance and
predictive modeling with advanced antibody engineering. Leveraging its INVYMAB platform approach, the company is generating a robust pipeline of product candidates which could be used in prevention or treatment of serious viral diseases, starting
with <FONT STYLE="white-space:nowrap">COVID-19</FONT> and expanding into influenza and other high-need indications. Visit&nbsp;https://invivyd.com/&nbsp;to learn more. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Note Regarding Forward Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as
&#147;anticipates,&#148; &#147;believes,&#148; &#147;could,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;potential,&#148; &#147;projects,&#148; and &#147;future&#148; or similar expressions (as well as other words or expressions referencing
future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, the company&#146;s ongoing research and clinical development plans for
VYD222 or any other product candidate, and the timing thereof, including with respect to the ongoing CANOPY phase 3 pivotal clinical trial and other research and development plans for VYD222; the company&#146;s regulatory and commercialization plans
for VYD222 or any other product candidate, and the timing thereof; the potential of VYD222 for strong clinical protection from symptomatic <FONT STYLE="white-space:nowrap">COVID-19</FONT> based on early signals observed in the CANOPY clinical trial;
the company&#146;s belief that the initial results from the CANOPY clinical trial are supportive of an immunobridging approach for the development of VYD222; the ability of the company to determine the sVNA titer levels against new <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> variants as they emerge using <I>in vitro </I>VYD222 potency data; the continued and ongoing <I>in vitro</I> neutralization activity of VYD222 against relevant and
major <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> variants; the company&#146;s belief that the demonstrated durability of VYD222 is reflective of its strategy to select antibody candidates that target
conservative epitopes to achieve its stated goal of keeping pace with viral evolution; the company&#146;s belief that VYD222 holds the potential to be an important preventive option for immunocompromised populations; the potential scope of an EUA
for VYD222, if granted, including disease state and patient population; the potential for VYD222 to maintain an EUA, if granted, through evolution of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT>
variants; the company&#146;s continued preparations and plans for commercial launch of VYD222 and the ability to have VYD222 commercially available rapidly, if EUA is granted; the company&#146;s ability to rapidly and perpetually deliver
antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, beginning with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2;</FONT></FONT> the company&#146;s
plans to generate a robust pipeline of product candidates which, if authorized or approved, could be used in prevention or treatment of serious viral diseases, starting with <FONT STYLE="white-space:nowrap">COVID-19</FONT> and expanding into
influenza and other high-need indications; and other statements that are not historical fact. The company may not actually achieve the plans, intentions or expectations disclosed in the company&#146;s forward-looking statements and you should not
place undue reliance on the company&#146;s forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the company&#146;s actual results to differ materially from the results described in or implied
by the forward-looking statements, including, without limitation: the timing and progress of the company&#146;s discovery, preclinical and clinical development activities; the company&#146;s ability to generate the clinical data needed from the
CANOPY clinical trial to support a potential EUA for VYD222; the company&#146;s interactions with the U.S. FDA regarding the EUA submission for VYD222; the outcome of the VYD222 EUA submission and timing thereof; the development and regulatory
pathways for authorization or approval of VYD222 or other product candidates; unexpected safety or efficacy data observed during preclinical studies or clinical trials; the predictability of clinical success of VYD222 or other product candidates
based on neutralizing activity in preclinical studies; the risk that results of preclinical studies or clinical trials may not be predictive of future results in connection with current or future clinical trials; the company&#146;s reliance on third
parties with respect to virus assay creation and product candidate testing and with respect to its clinical trials; variability of results in models used to predict activity against
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> variants of concern; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory
authorization or approval process; whether VYD222 or any other product candidate is able to demonstrate and sustain neutralizing activity against relevant, major or predominant
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> variants, particularly in the face of viral evolution; the ability to maintain a continued acceptable safety, tolerability and efficacy profile of VYD222 or
any other product candidate following EUA or approval, if granted; whether the company&#146;s product candidates will be high-quality, long-lasting antibodies that resist viral escape; whether the company is able to successfully submit an EUA for
any other product candidate in the future, and the outcome and timing of any such EUA submission; the company&#146;s ability to manufacture sufficient commercial quantities of VYD222; the complexities of manufacturing monoclonal antibody therapies
and the company&#146;s reliance on contract manufacturers to do so; the company&#146;s ability to establish a sales, marketing and distribution infrastructure to commercialize VYD222 or any other product candidates for which the company may obtain
regulatory approval or EUA; whether the company can obtain and maintain third-party coverage and adequate reimbursement for VYD222 or any other product candidate; whether the company&#146;s research and development efforts will identify and result
in safe and effective therapeutic options for infectious diseases other than <FONT STYLE="white-space:nowrap">COVID-19;</FONT> the company&#146;s ability to continue as a going concern; and whether the company has adequate funding to meet future
operating expenses and capital expenditure requirements. Other factors that may cause the company&#146;s actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under
the heading &#147;Risk Factors&#148; in the company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2022 filed with the Securities and Exchange Commission (SEC), and in the
company&#146;s other filings with the SEC, and in its future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this press release are made as of this date, and Invivyd undertakes no duty to update
such information whether as a result of new information, future events or otherwise, except as required under applicable law. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"># # # </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contacts: </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scott Young </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(781) <FONT STYLE="white-space:nowrap">208-1747</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>syoung@invivyd.com </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gabriella Linville-Engler </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(781) <FONT STYLE="white-space:nowrap">208-0160</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>gengler@invivyd.com</U> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ivvd-20240103.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 1/3/2024 1:28:00 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2023"
  xmlns:ivvd="http://invivyd.com/20240103"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://invivyd.com/20240103"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" namespace="http://xbrl.sec.gov/naics/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ivvd-20240103_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ivvd-20240103_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://invivyd.com//20240103/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>ivvd-20240103_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 1/3/2024 1:28:00 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>ivvd-20240103_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 1/3/2024 1:28:00 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://invivyd.com//20240103/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="ivvd-20240103.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://invivyd.com//20240103/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g277393g0103035319803.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g277393g0103035319803.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  E /L# 2(  A$! Q$!_\0
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MX(\@\"?\C_H'_7]'_.OK6ODKP)_R/^@?]?T?\Z^M:>,^) B.X_X]I?\ </\
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5-@N1Z#LH]A^.:ZNBBO(E)R=V4?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140543808180256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jan. 03, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001832038<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan.  03,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Invivyd, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">85-1403134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1601 Trapelo Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Waltham<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(781)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">819-0080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IVVD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>d277393d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ivvd-20240103.xsd" xlink:type="simple"/>
    <context id="duration_2024-01-03_to_2024-01-03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832038</identifier>
        </entity>
        <period>
            <startDate>2024-01-03</startDate>
            <endDate>2024-01-03</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2024-01-03_to_2024-01-03">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2024-01-03_to_2024-01-03"
      id="Hidden_dei_EntityCentralIndexKey">0001832038</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2024-01-03_to_2024-01-03">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2024-01-03_to_2024-01-03">2024-01-03</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2024-01-03_to_2024-01-03">Invivyd, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2024-01-03_to_2024-01-03">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2024-01-03_to_2024-01-03">001-40703</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2024-01-03_to_2024-01-03">85-1403134</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2024-01-03_to_2024-01-03">1601 Trapelo Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2024-01-03_to_2024-01-03">Suite 178</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2024-01-03_to_2024-01-03">Waltham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2024-01-03_to_2024-01-03">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2024-01-03_to_2024-01-03">02451</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2024-01-03_to_2024-01-03">(781)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2024-01-03_to_2024-01-03">819-0080</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2024-01-03_to_2024-01-03">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2024-01-03_to_2024-01-03">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2024-01-03_to_2024-01-03">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2024-01-03_to_2024-01-03">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2024-01-03_to_2024-01-03">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2024-01-03_to_2024-01-03">IVVD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2024-01-03_to_2024-01-03">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2024-01-03_to_2024-01-03">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2024-01-03_to_2024-01-03">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MX@RFIZT SU=2FH^"/?17WVQ&_P)02P,$%     @ W3@C6)^@&_"Q @  X@P
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M$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ W3@C6 =!36*!    L0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M" #=."-8:\&#9.X    K @  $0              @ &O    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    " #=."-8F5R<(Q &  "<)P  $P
M    @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( -TX(UA!
M0>VT>00  +\1   8              " @0T(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    " #=."-8GZ ;\+$"  #B#   #0
M    @ &\#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( -TX(UB7BKL<P
M !,"   +              "  9@/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M -TX(U@<.&7J/P$  #P"   /              "  8$0  !X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    " #=."-8)!Z;HJT   #X 0  &@
M@ 'M$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #=
M."-899!YDAD!  #/ P  $P              @ '2$@  6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     "0 ) #X"   <%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d277393d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://invivyd.com//20240103/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d277393d8k.htm">d277393d8k.htm</File>
    <File>ivvd-20240103.xsd</File>
    <File>ivvd-20240103_lab.xml</File>
    <File>ivvd-20240103_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d277393d8k.htm": {
   "nsprefix": "ivvd",
   "nsuri": "http://invivyd.com/20240103",
   "dts": {
    "inline": {
     "local": [
      "d277393d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "ivvd-20240103.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "ivvd-20240103_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ivvd-20240103_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 24
   },
   "report": {
    "R1": {
     "role": "http://invivyd.com//20240103/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2024-01-03_to_2024-01-03",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d277393d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2024-01-03_to_2024-01-03",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d277393d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://invivyd.com//20240103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://invivyd.com//20240103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://invivyd.com//20240103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://invivyd.com//20240103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://invivyd.com//20240103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://invivyd.com//20240103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://invivyd.com//20240103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://invivyd.com//20240103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://invivyd.com//20240103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://invivyd.com//20240103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://invivyd.com//20240103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://invivyd.com//20240103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://invivyd.com//20240103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://invivyd.com//20240103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://invivyd.com//20240103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://invivyd.com//20240103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://invivyd.com//20240103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://invivyd.com//20240103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://invivyd.com//20240103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://invivyd.com//20240103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://invivyd.com//20240103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://invivyd.com//20240103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://invivyd.com//20240103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://invivyd.com//20240103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001193125-24-001013-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-24-001013-xbrl.zip
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MU_J<]<@5NZ5.= -;ZC1@+<XSHVLIF0(]N&Z$<IX+_YT!_:\07/P'4$L#!!0
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M 3AI:B!>8%,^DG#J7"!.(ZXRG<>G]Y/Y,N [2F],S/3RV!9#<,PQHCSC(-\
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M5DT*@6\_NH*VF.5U@D]COW%!#Q[IX8BD5(R=1E97ZMRZBK\OLNLS*L;#,*P
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M2:E::\L:2)@2"=Q\0796UT(H@)P<O=QTFB0K5;7:]S+1/'/0<=Y8JIEXH:0
M"#Y^F\$8D)-F=]%1YKFN1D14T_3+A'&YYQ#H1,K2E:#860[<I[_Q X) P5@=
M@Z9<[=<][@U-.18[1-O>F,,TJB$A3.9TX5CVX6+'[[8WU\M)GF9-_[N0[47O
MNGO<6Z?8[ UJN<E'Q@9&R8!19D7E\H/4.Z*;)$A1@H\W+,C!*&X+YN);*8AW
M,;B.%+1S!,J49/3BY'K=F9E.!P75%SO/'</]J@\KQ&L"TR^SR B?M#K[ ET
ML\. %2SC&>MAXD,#&8F:6W@F'!:\0VSO;M'[O:"#G*D+F>#I?3,O<C#=4KY.
MW%</Q$PJ@,^ IJ\547+A3;2)XV0[WR^;BZOVAZ.+-O!LH.V8FJ;-ML'W>$4^
MLJ9 QOPKU;CR478W!7L:YNCC.9#*Q_U0=H.];8KQT"7JM;;$';CT(RFC7\X/
MH(Q5/^;>YBHYXAW=U1?C;G^]:M.0+&.J$9@)DZ5GP-EF27-B)IP4F31KE<W&
M9671CB_D)K>M6E$5(DI\PV%U9=FMGMF-C74M$?'&.;>_N3'I(A-JMA#)&H-@
M<+<A5E\+AWE691/#!.FO=AI\Q1D @K0F\[:MK4-.$CC7#:@-EF,?RE63'M!8
MG"OU'H5<LBZMU"RI5E?9&N$C _VT"OHLF">TADZ]_1463"VL,HNAE[%M@PZ7
M/5H(?L075:W*_9.#$!:K^H#[I%D3#0_!=?7J@<PR>9LM*0_<,V)P/M9@^FF9
M'&%Y_J/:Z%6]A=YZ3(H>4B%)*0?P0G&08C95)T5E!A1H5=6ITZQDN+BKBI#H
MI+"F7U :Z (7,S1L[(L<*E^)K[6! YA26U')%'(<%%79#I(<NL[*,@+G1GZ
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MU'5!JK@#R> FY\>?\2%_ _3_ 5!+ P04    " #=."-8VH2-OCP#   \"P
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MT<AUOCMPI[$+N%FI_9&WS![&=;=]K?H)9ILCW-T,1[V]:E<-_?P%4$L#!!0
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M0\"^0A.9^0T\ELD?8\0"OB4#)MIM7)1W7*DM_=>%\ETT^QL[:L__4$L#!!0
M   ( -TX(UBDUCI3V00  /0M   5    :79V9"TR,#(T,#$P,U]P<F4N>&UL
MU9I=C^(V%(;O5]K_X*8WK;0A),QN=] P*\K,5*CS@8!MJ]ZL3'( JXZ-[/#U
M[WL<\)9 F(79417/Q0")W^/WG,>8V,G5IU7*R0*49E*TO+!6]PB(6"9,3%K>
M7/M4QXQY1&=4))1+ 2UO#=K[=/WVS=4/OD]N[KJ/Q"?3+)OI9A LE\M:,F9"
M2S[/,*2NQ3(-B._;]IWA9_+'IKLFZ0,'JH&D5&>@R*]SQI-F5(\:83V,:M&N
M3 $U\4A",VB2,&@$V.Z"A,WH8[->)[T'<IL'$63(4MA5RME:L<DT(S_%/Y-<
M=".% ,YA3>Z8H")FE).!-?R.=$5<(VW.2=_(-+K4H!:0U+91.1/_-,V_D?%.
MWKXA^(=E%#H_VO),,;:U6(T4KTDU0;?U1F!%WJYF=2!:-G))>'EY&>1GB^TU
M*VN-'83!7P_W@W@**?41 2*+][I"-TGV5;UK[GVP.6G;:];4>:1[&>>5/R$M
M<K2%^>3;9KXYY(>1WPAK*YUXUZ;+3565Y-"',3&OG_O=KWTRL6"+=9(/IAQ\
M/<2H&5U)(=-U8)H'-S*>IR R^]H6R:W(6+;NBK%4:9Z$1_)Z-J<*QBV/+1:)
M;Z,9*S_V,="7<P)EZQE^(S1+9QP\$NRD,E,X;$26M[[' P4!K#(0"20VC$G@
M]9.]WK#<#E@9%Y*WW]@<E(:X-I&+( %F>FR8-Z8RFZK@AR\=B9-$>Z0S1>.L
MF#TW(T0J>Y#3$?"65R(*7M-0&]-.3.IWG$Y.-;0G*AK:)=96<2$D5;$-AV\+
MN Y'^[9%,*,*X_GQ%*<UJQXKF9869]N;+#4J50*JY451#;_E'IDI)A7"QB,>
MF6OT(F?&->7F'(Q!*4CN-VD?=9E;Q!E30][RE?%L1F,',U"4=W&LKWZ']:F8
MCHBKB^N(88NMX0PV.Y\,L8RGTBIJJ@NIZ-.R>>\<FQZ@5YSNDQN\%CH7TIZX
M^K3V#%ML'YS!MID;^C!A)E&1/=+T9&KEVNI"*_=KF?WB&#-<"$@UDRHO[0 K
M#!TYQRE^W9')F0B_$:KJ1+]AWP+^Z!C@.\;A<9Z.0)U'<U=7=72[7BVG2\<X
M#>FJFV 9V)AM%J,O@78T2-4)'C6^Q=FH.X:SG2189+U]P<4QA.>A+ U0=8RE
MIBW"T'F$T?<BC%Q$&/V'T+6U^3:+#KY]4D.Y%"\"N"MW!-^N90O/G15Z(97\
M4NQ)]91<,+/9^Q*"!S$<P7C@V[*\<)-E3^J,\K_9[/S517D$1SCNN;84W=F7
M,?-)6P$]AUM14UU219^6C3N;+^;N%>]-I3ASG7>HJRZC0Z^6DSL;+G^BOPQ$
M1Z;I7&R7.?I46$?$U25VQ+#%YLXVRD!R%K.,B<D#_A@K9JR=QJQ,65U@96XM
M+7<V4WH*S) #O%K*[X.86]#J:3P^?5I\+D)UZ3WG>DOQPIT]E+ULNEK/07T_
MRY(XSA M\6ZYNK.Q,H!X;BR&T6C(,G[RI>2AKKK<#KU:3N[LG@P5-4_'#=;I
M2)[\<[<GJBZA/:,6CSO[(W:(W:[B*143..=V:[FVNK#*_5IFKNV#W*:@)CCV
M?E-RF4UQ?I]1<>8C0T="5)?@L[8M2'>V0K;IK' 6$9H9<YO'-\ZD6**O/,(2
MSY;?_[!=<A4<U.4>#YC'E3=GS#_S\"T>^1=02P$"% ,4    " #=."-8+@+)
M\K\.  #E8P  #@              @ $     9#(W-S,Y,V0X:RYH=&U02P$"
M% ,4    " #=."-8 FF5$'@7   (6@  $0              @ 'K#@  9#(W
M-S,Y,V1E>#DY,2YH=&U02P$"% ,4    " #=."-8VH2-OCP#   \"P  $0
M            @ &2)@  :79V9"TR,#(T,#$P,RYX<V102P$"% ,4    " #=
M."-8. 0.3J@&  "C20  %0              @ ']*0  :79V9"TR,#(T,#$P
M,U]L86(N>&UL4$L! A0#%     @ W3@C6*36.E/9!   ]"T  !4
M     ( !V#   &EV=F0M,C R-# Q,#-?<')E+GAM;%!+!08     !0 % $ !
(  #D-0     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
